Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy

Area of Science:

• Oncology
• Dermatology
• Medical Imaging

Background:

• Reducing late-stage melanoma and identifying high-risk patients are critical for effective treatment.
• Early-stage melanoma is often treatable with surgery.
• Accurate prognosis is essential for managing and following melanoma patients.

Purpose of the Study:

• To review current advancements in melanoma screening, prognostic factor identification, and therapeutic strategies.
• To highlight the role of adjuvant and neoadjuvant therapies in managing high-risk and advanced melanoma.
• To discuss the evolving landscape of melanoma detection and treatment.

Main Methods:

• Review of population-based screening programs, mobile health technologies, and advanced imaging tools.
• Analysis of prognostic factors including clinical covariates and molecular markers.
• Examination of regulatory-approved adjuvant therapies (interferon alpha, pegylated interferon alpha, ipilimumab) and ongoing neoadjuvant therapy studies.

Main Results:

• Improved screening methods enhance early detection.
• Prognostic markers aid in patient subclassification for tailored management.
• Adjuvant therapies show benefits in relapse-free survival, with some improving overall survival.
• Neoadjuvant therapy research shows promising clinical activity and biomarker insights.

Conclusions:

• Early detection and accurate prognosis are key to improving melanoma patient outcomes.
• Adjuvant and neoadjuvant therapies represent important strategies for managing high-risk and advanced melanoma.
• Ongoing research continues to refine melanoma screening, prognostication, and treatment paradigms.